CClinicalTrials.gg
CompletedNCT00140634Updated May 11, 2021

The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients

An observational study in Articular Cartilage and Cartilage Diseases, sponsored by Vericel Corporation. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Vericel Corporation · Observational

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
2,233
Sex
All
01

Study summary

The objectives of the Cartilage Repair Registry is to report the long term efficacy and safety of cartilage repair procedures in Registry patients.

02

Conditions studied

  • Articular Cartilage
  • Cartilage Diseases

Browse trials for

03

In context

Cartilage Diseases

73 studies on the registry are indexed under Cartilage Diseases; 5 are open to participants now.

This study's enrollment of 2,233 is above the median of 80 across 19 observational studies indexed under Cartilage Diseases.

Browse Cartilage Diseases studies →

Lead sponsor

Vericel Corporation is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Registry of patients with diagnosis of chondral injury.

Inclusion criteria

  • All registry patients meeting the cohort definition at the pre-operative visit will be included on the overall summary tables for the patient cohort

Exclusion criteria

Exclusion Criteria:

  • All registry patients meeting the cohort definition at the pre-operative visit will be included on the overall summary tables for the patient cohort
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
2,233 participants (actual)
Patient registry
No

Interventions

  • BiologicalCarticel (autologous cultured chondrocyte) implantation

    Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.

06

What researchers measure

Primary outcomes

  1. Physician assessment of effectiveness of autologous chondrocyte implantation

    Overall assessment of the patient by the physician based on knee examination and progress of rehabilitation

    Time frame: 6 month post implantation

  2. Physician assessment of effectiveness of autologous chondrocyte implantation

    Overall assessment of the patient by the physician based on knee examination and progress of rehabilitation

    Time frame: 12 month post implantation

  3. Physician assessment of effectiveness of autologous chondrocyte implantation

    Overall assessment of the patient by the physician based on knee examination and progress of rehabilitation

    Time frame: 24 month post implantation

Secondary outcomes

  1. Patient assessment of effectiveness of autologous chondrocyte implantation

    Overall assessment of the patient by the patient based on pain, swelling, giving-way, grinding, stiffness, catching and locking and quantity of exercise

    Time frame: 6 month post implantation

07

Study locations

1 site
  • Registry contains data from patients whom were implanted by 1123 surgeons in the U.S. and also data captured on patients treated by 154 surgeons in 15 other countries.
    Cambridge, Massachusetts 02142, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00140634
Lead sponsor
Vericel Corporation
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Mar 1995
Primary completion
Jan 2009
Completion
Jan 2009
Last update
May 11, 2021

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion